Indivior Pharmaceuticals Inc Dossier - Source-backed chat

Indivior Pharmaceuticals Inc

INDVNASDAQ

SectorHealth Care

IndustryDrug Manufacturers - Specialty & Generic

Beta (adjusted)1.09

Intrinsic Value $60.42median of 4 methods · middle span $20-$101based on filings through 30 Jun 2026

Market Price $35.38Price as of 1 Oct 2026

Significantly undervaluedIntrinsic value is 71% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

marker beyond scale (+71%)

Data confidence Sign in to view data confidence

Market Cap $4.2B

Enterprise Value $4.4B

Shares Outstanding 130M diluted

Moat Rating None

Next Earnings Date5 Nov 2026

Last ex-dividend16 Jun 2016

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Indivior Pharmaceuticals, Inc. is successfully executing Phase II (Accelerate) of its Action Agenda, transitioning from a cost-rationalization story to a high-margin revenue growth engine. The company's flagship long-acting injectable (LAI) treatment for opioid use disorder (OUD), SUBLOCADE, continues to dominate the market with a stable 76% category share. Following a simplified operating model established in Phase I, Indivior is delivering significant operating leverage, with Q1 2026 Adjusted EBITDA more than doubling year-over-year to $164 million (52% margin). Management's upward revision of FY 2026 guidance reflects robust demand signals, record new patient starts, and stable pricing for SUBOXONE Film. With a strengthened balance sheet, a $175 million accelerated share repurchase program underway, and a low valuation relative to its near-term earnings growth potential, Indivior presents an attractive risk-reward profile for growth and value investors alike.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026

Low · most bearish analyst$43.00

Mean target$49.00

High · most bullish analyst$53.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

SUBLOCADE growth moderates faster than expected due to competitive pressures in the long-acting injectable market. Gross-to-net adjustments act as a severe headwind, and faster-than-expected share erosion of SUBOXONE Film impacts the top line. Pipeline setbacks leave the company highly concentrated on a single product, limiting multiple expansion.

Base CaseCentral scenario

SUBLOCADE continues its strong adoption trajectory, driving FY 2026 net revenue to the midpoint of raised guidance ($1.25 billion) and SUBLOCADE net revenue to $970 million. Operating leverage from the simplified cost structure sustains Adjusted EBITDA margins at approximately 51%, yielding $640 million in Adjusted EBITDA. Share repurchases continue to support EPS growth, and the company successfully navigates generic competition for older products.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Flagship product SUBLOCADE maintains a dominant 76% market share in the rapidly growing U.S. long-acting injectable OUD treatment market.
Significant operating leverage from Phase I restructuring, delivering a 112% year-over-year increase in Q1 2026 Adjusted EBITDA and a 52% margin.
Active capital return program, including a $175 million accelerated share repurchase agreement executed in May 2026.
Strengthened balance sheet following a $500 million convertible senior notes offering at 0.625%, which repaid high-interest term debt.

Key Investment Risks

High product concentration risk, with the company's growth narrative heavily dependent on the commercial execution of SUBLOCADE.
Potential pricing pressures and gross-to-net adjustments acting as headwinds in the latter half of 2026.
Pipeline setbacks, including the decision not to advance INDV-6001 to Phase III and the discontinuation of internal development for INDV-2000 in OUD.
Ongoing legal and regulatory exposure tied to legacy antitrust and opioid litigation.

Thesis Invalidation Triggers

SUBLOCADE dispense unit growth falling below double digits.
A material decline in SUBLOCADE's market share among long-acting injectables due to new competitive entries.
Unexpected regulatory or reimbursement changes affecting Medicaid coverage, which accounts for approximately 70% of SUBLOCADE's dispensed units.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.